Surendra M, et al. - In this single center prospective open label observational study, researchers evaluated the safety and efficacy of Ledipasvir and Sofosbuvir in hemodialysis (HD) patients who were diagnosed with hepatitis C virus (HCV) genotype 1 infection. Only treatment naive HD patients with normal liver histology were eligible. Sustained virological response (SVR12) and discontinuation of therapy secondary to adverse drug effects was assessed following treatment with Ledipasvir and Sofosbuvir combination tablet on alternate days for a period of 12 weeks. A treatment regimen comprising Ledipasvir and Sofosbuvir combination therapy on alternate days provided excellent SVR12 rates and effective even in end stage renal disease patients. Moreover, no major adverse reactions were reported and it was as safe as in other population groups.